Q3 EPS Forecast for Vir Biotechnology Decreased by Analyst

Vir Biotechnology, Inc. (NASDAQ:VIR) – Investment analysts at HC Wainwright cut their Q3 2026 earnings per share (EPS) estimates for shares of Vir Biotechnology in a research note issued on Monday, August 10th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings of ($0.83) per share for the quarter, down from their previous estimate of ($0.71). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Vir Biotechnology’s current full-year earnings is ($2.06) per share. HC Wainwright also issued estimates for Vir Biotechnology’s Q4 2026 earnings at ($0.72) EPS, FY2026 earnings at ($1.89) EPS, Q1 2027 earnings at ($0.77) EPS, Q2 2027 earnings at ($0.61) EPS, Q3 2027 earnings at ($0.51) EPS, Q4 2027 earnings at ($0.48) EPS, FY2027 earnings at ($2.37) EPS, FY2028 earnings at ($1.70) EPS, FY2029 earnings at ($1.25) EPS and FY2030 earnings at ($0.34) EPS.

Vir Biotechnology (NASDAQ:VIR) last released its quarterly earnings data on Wednesday, August 5th. The company reported $0.47 earnings per share for the quarter, beating the consensus estimate of $0.33 by $0.14. Vir Biotechnology had a negative return on equity of 29.99% and a negative net margin of 638.88%.The business had revenue of $238.95 million for the quarter, compared to analysts’ expectations of $135.88 million. During the same quarter in the previous year, the business posted ($0.80) EPS. Vir Biotechnology’s revenue for the quarter was up 19582.5% on a year-over-year basis.

Several other equities research analysts have also issued reports on the stock. Morgan Stanley set a $25.00 price target on shares of Vir Biotechnology in a research note on Thursday, August 6th. Wall Street Zen upgraded Vir Biotechnology from a “sell” rating to a “hold” rating in a report on Saturday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vir Biotechnology in a research report on Wednesday, July 8th. Finally, Leerink Partners upped their target price on Vir Biotechnology from $20.00 to $21.00 and gave the stock an “outperform” rating in a report on Wednesday, June 3rd. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $20.62.

Vir Biotechnology Stock Up 0.4%

Shares of VIR stock opened at $8.93 on Wednesday. Vir Biotechnology has a 12-month low of $4.25 and a 12-month high of $11.66. The firm has a fifty day moving average of $9.29 and a 200-day moving average of $9.10. The company has a market capitalization of $1.51 billion, a price-to-earnings ratio of -4.80 and a beta of 1.66.

Insider Buying and Selling

In other news, Director Janet Napolitano sold 3,200 shares of Vir Biotechnology stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $9.45, for a total value of $30,240.00. Following the completion of the transaction, the director owned 21,216 shares of the company’s stock, valued at $200,491.20. This trade represents a 13.11% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.90% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Vir Biotechnology

A number of institutional investors and hedge funds have recently modified their holdings of VIR. BlackRock Inc. bought a new stake in shares of Vir Biotechnology during the 2nd quarter worth about $210,712,000. GSK plc bought a new position in Vir Biotechnology in the 4th quarter valued at about $51,562,000. ADAR1 Capital Management LLC bought a new position in Vir Biotechnology in the 1st quarter valued at about $24,593,000. Pictet Asset Management Holding SA lifted its position in Vir Biotechnology by 10,878.9% during the first quarter. Pictet Asset Management Holding SA now owns 1,480,828 shares of the company’s stock worth $13,268,000 after acquiring an additional 1,467,340 shares during the last quarter. Finally, Balyasny Asset Management L.P. acquired a new stake in Vir Biotechnology during the fourth quarter worth approximately $8,252,000. 65.32% of the stock is owned by institutional investors.

Vir Biotechnology News Roundup

Here are the key news stories impacting Vir Biotechnology this week:

• Positive Sentiment: Bank of America Securities initiated or reiterated a Buy rating on Vir Biotechnology, providing a positive counterpoint to the recent estimate reductions. Vir Biotechnology Receives a Buy from Bank of America Securities
• Neutral Sentiment: Reported short interest was listed at zero shares as of August 11, unchanged from the prior period, with a zero-day short-interest ratio. Because the figures appear incomplete or anomalous, they offer little reliable insight into trading sentiment.
• Negative Sentiment: HC Wainwright lowered its 2026 EPS forecast to -$1.89 from -$1.55 and reduced its estimates for third-quarter 2026 EPS to -$0.83 from -$0.71 and fourth-quarter EPS to -$0.72 from -$0.60. The revisions point to larger anticipated losses in the near term.
• Negative Sentiment: The firm also cut its 2027 EPS forecast to -$2.37 from -$2.22, including reductions for the first, third and fourth quarters. Its 2028 and 2029 forecasts were lowered to -$1.70 and -$1.25, respectively, indicating a slower path toward profitability.
• Negative Sentiment: One offsetting revision was an increase in the 2027 second-quarter EPS estimate to -$0.61 from -$0.68, while the 2030 estimate improved modestly to -$0.34 from -$0.36. However, these upgrades were outweighed by the broader set of downward revisions. Overall, the analyst changes are likely contributing to a weaker stock price.

About Vir Biotechnology

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.